This article is more than 5 years old. Information may no longer be current.

Alimera reports 342% total net revenue increase in 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported total net revenue of $8.4 million in 2014, a 342% increase from approximately $1.9 million in 2013, according to a press release.

The company began to recognize revenue in the second quarter of 2013, after the commercial launch of Iluvien (fluocinolone acetonide intravitreal implant) in Germany and the United Kingdom.

Net revenue totaled $1.7 million in the fourth quarter 2014, an 81% increase from $0.9 million in net revenue in the fourth quarter 2013.

GAAP net loss attributable to common stockholders for 2014 was $36.7 million, compared with $51.2 million in 2013. Fourth-quarter net loss was $10 million, compared with $14.8 million the previous year.

Net loss per share attributable to common stockholders was $0.91 in 2014, compared with $1.62 in 2013. Net loss per share in the fourth quarter was $0.23, compared with $0.47 in the fourth quarter 2013.